CIK 0001576885 · <br>Emerging growth company
Acumen Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ABOS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364108129
- Phone
- 617-344-4190
- Business address
- 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON, MA, 02465
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Grant or award Chief Executive Officer acquired 299,800 shares (grant or award)
- 4 Grant or award CFO & Chief Business Officer acquired 99,133 shares (grant or award)
- 4 Grant or award Chief Legal Officer & Corp Sec acquired 99,133 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 99,133 shares (grant or award)
- 4 Grant or award Chief Operating Officer acquired 84,600 shares (grant or award)
- 4 Grant or award Chief Regulatory Officer acquired 84,600 shares (grant or award)
- 4 Grant or award President and CDO acquired 166,867 shares (grant or award)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Open-market sale CFO & Chief Business Officer sold 6,888 shares at $1.82 ($12,513)
- 4 Open-market sale Chief Operating Officer sold 3,530 shares at $1.86 ($6,562)
- 4 Open-market sale Chief Legal Officer & Corp Sec sold 50,659 shares at an average $1.80 ($91,073)
- 4 Open-market sale Chief Executive Officer sold 26,472 shares at an average $1.77 ($46,954)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
Page 4 of 19 · 365 filings